1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

The Vaginal Microbiota and Urinary Tract Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Author: Ann E. Stapleton1
  • Editors: Matthew A. Mulvey2, Ann E. Stapleton3, David J. Klumpp4
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98195; 2: University of Utah, Salt Lake City, UT; 3: University of Washington, Seattle, WA; 4: Northwestern University, Chicago, IL
  • Source: microbiolspec December 2016 vol. 4 no. 6 doi:10.1128/microbiolspec.UTI-0025-2016
  • Received 22 August 2016 Accepted 15 November 2016 Published 16 December 2016
  • Ann E. Stapleton, stapl@uw.edu
image of The Vaginal Microbiota and Urinary Tract Infection
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    The Vaginal Microbiota and Urinary Tract Infection, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/6/UTI-0025-2016-1.gif /docserver/preview/fulltext/microbiolspec/4/6/UTI-0025-2016-2.gif
  • Abstract:

    The vagina is a key anatomical site in the pathogenesis of urinary tract infection (UTI) in women, serving as a potential reservoir for infecting bacteria and a site at which interventions may decrease the risk of UTI. The vaginal microbiota is a dynamic and often critical factor in this pathogenic interplay, because changes in the characteristics of the vaginal microbiota resulting in the loss of normally protective spp. increase the risk of UTI. These alterations may result from the influence of estrogen deficiency, antimicrobial therapy, contraceptives, or other causes. Interventions to reduce adverse effects on the vaginal microbiota and/or to restore protective lactobacilli may reduce the risks of UTI.

  • Citation: Stapleton A. 2016. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectrum 4(6):UTI-0025-2016. doi:10.1128/microbiolspec.UTI-0025-2016.

Key Concept Ranking

Urinary Tract Infections
0.5329633
Lactobacillus jensenii
0.4799739
0.5329633

References

1. CDC. 2010. NAMCS and NHAMCS Web Tables. Table 1. Annual number and percent distribution of ambulatory care visits by setting type according to diagnosis group: United States, 2009-2010. http://www.cdc.gov/nchs/ahcd/web_tables.htm.
2. Foxman B. 2014. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28:1–13. [PubMed]
3. Hooton TM, Scholes D, Hughes JP, Winter C, Roberts PL, Stapleton AE, Stergachis A, Stamm WE. 1996. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335:468–474. [PubMed]
4. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. 2007. Community-onset urinary tract infections: a population-based assessment. Infection 35:150–153. [PubMed]
5. Engel JD, Schaeffer AJ. 1998. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am 25:685–701, x. [PubMed]
6. Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. 2000. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10:509–515. [PubMed]
7. Hooton TM, Stamm WE. 1997. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 11:551–581. [PubMed]
8. Hooton TM, Gupta K. 2016. Recurrent urinary tract infection in women. UpToDate, Waltham, MA. (accessed 5 June 2016.)
9. Gupta K, Bhadelia N. 2014. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am 28:49–59. [PubMed]
10. Czaja CA, Stamm WE, Stapleton AE, Roberts PL, Hawn TR, Scholes D, Samadpour M, Hultgren SJ, Hooton TM. 2009. Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women. J Infect Dis 200:528–536. [PubMed]
11. Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. 1995. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis 172:440–445. [PubMed]
12. Beerepoot M, Geerlings S. 2016. Non-antibiotic prophylaxis for urinary tract infections. Pathogens 5:5. [PubMed]
13. Ravel J, Brotman RM. 2016. Translating the vaginal microbiome: gaps and challenges. Genome Med 8:35. [PubMed]
14. Antonio MA, Hawes SE, Hillier SL. 1999. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 180:1950–1956. [PubMed]
15. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, Holmes KK. 1989. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 27:251–256. [PubMed]
16. Lepargneur JP. 2016. Lactobacillus crispatus as biomarker of the healthy vaginal tract. Ann Biol Clin (Paris) 74:421–427.
17. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, Jespers V. 2014. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One 9:e105998. doi:10.1371/journal.pone.0105998. [PubMed]
18. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. 2011. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 108(Suppl 1):4680–4687. [PubMed]
19. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner-Hanssen P, Holmes KK. 1996. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis 174:1058–1063. [PubMed]
20. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, Mandaliya K, Ndinya-Achola JO, Bwayo J, Kreiss J. 1999. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180:1863–1868. [PubMed]
21. Schwebke JR. 2001. Role of vaginal flora as a barrier to HIV acquisition. Curr Infect Dis Rep 3:152–155. [PubMed]
22. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG. 1998. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12:1699–1706. [PubMed]
23. van De Wijgert JH, Mason PR, Gwanzura L, Mbizvo MT, Chirenje ZM, Iliff V, Shiboski S, Padian NS. 2000. Intravaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis 181:587–594. [PubMed]
24. Zheng HY, Alcorn TM, Cohen MS. 1994. Effects of H2O2-producing lactobacilli on Neisseria gonorrhoeae growth and catalase activity. J Infect Dis 170:1209–1215. [PubMed]
25. Boris S, Barbés C. 2000. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2:543–546. [PubMed]
26. Herthelius M, Gorbach SL, Möllby R, Nord CE, Pettersson L, Winberg J. 1989. Elimination of vaginal colonization with Escherichia coli by administration of indigenous flora. Infect Immun 57:2447–2451. [PubMed]
27. McGroarty JA, Reid G. 1988. Detection of a Lactobacillus substance that inhibits Escherichia coli. Can J Microbiol 34:974–978. [PubMed]
28. McGroarty JA, Tomeczek L, Pond DG, Reid G, Bruce AW. 1992. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. J Infect Dis 165:1142–1144. [PubMed]
29. Osset J, Bartolomé RM, García E, Andreu A. 2001. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 183:485–491. [PubMed]
30. Reid G, Cook RL, Bruce AW. 1987. Examination of strains of lactobacilli for properties that may influence bacterial interference in the urinary tract. J Urol 138:330–335. [PubMed]
31. Reid G, Heinemann C, Velraeds M, van der Mei HC, Busscher HJ. 1999. Biosurfactants produced by Lactobacillus. Methods Enzymol 310:426–433. [PubMed]
32. Stamey TA, Kaufman MF. 1975. Studies of introital colonization in women with recurrent urinary infections. II. A comparison of growth in normal vaginal fluid of common versus uncommon serogroups of Escherichia coli. J Urol 114:264–267. [PubMed]
33. Andreu A, Stapleton AE, Fennell CL, Hillier SL, Stamm WE. 1995. Hemagglutination, adherence, and surface properties of vaginal Lactobacillus species. J Infect Dis 171:1237–1243. [PubMed]
34. Butler D, Silvestroni A, Stapleton A. 2016. Cytoprotective effect of Lactobacillus crispatus CTV-05 against uropathogenic E. coli. Pathogens 5:27.
35. O’Hanlon DE, Moench TR, Cone RA. 2013. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One 8:e80074. doi:10.1371/journal.pone.0080074. [PubMed]
36. Hooton TM, Stamm WE. 1996. The vaginal flora and urinary tract infections. In Warren JW, Mobley HL (ed), Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. ASM Press, Washington, DC.
37. Schaeffer AJ, Jones JM, Amundsen SK. 1980. Bacterial effect of hydrogen peroxide on urinary tract pathogens. Appl Environ Microbiol 40:337–340. [PubMed]
38. Klebanoff SJ, Hillier SL, Eschenbach DA, Waltersdorph AM. 1991. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J Infect Dis 164:94–100. [PubMed]
39. Pfau A, Sacks T. 1981. The bacterial flora of the vaginal vestibule, urethra and vagina in premenopausal women with recurrent urinary tract infections. J Urol 126:630–634. [PubMed]
40. Stamey TA, Sexton CC. 1975. The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol 113:214–217. [PubMed]
41. Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. 1998. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis 178:446–450. [PubMed]
42. Hooton TM, Fihn SD, Johnson C, Roberts PL, Stamm WE. 1989. Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch Intern Med 149:1932–1936. [PubMed]
43. Hooton TM, Roberts PL, Stamm WE. 1994. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis 19:274–278. [PubMed]
44. Kirjavainen PV, Pautler S, Baroja ML, Anukam K, Crowley K, Carter K, Reid G. 2009. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin Vaccine Immunol 16:29–36. [PubMed]
45. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. 2005. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 293:949–955. [PubMed]
46. Raz R. 2011. Urinary tract infection in postmenopausal women. Korean J Urol 52:801–808. [PubMed]
47. Raz R. 2001. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. J Infect Dis 183(Suppl 1):S74–S76. [PubMed]
48. Raz R, Stamm WE. 1993. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756. [PubMed]
49. Cauci S, Driussi S, De Santo D, Penacchioni P, Iannicelli T, Lanzafame P, De Seta F, Quadrifoglio F, de Aloysio D, Guaschino S. 2002. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol 40:2147–2152. [PubMed]
50. Muhleisen AL, Herbst-Kralovetz MM. 2016. Menopause and the vaginal microbiome. Maturitas 91:42–50. [PubMed]
51. Pabich WL, Fihn SD, Stamm WE, Scholes D, Boyko EJ, Gupta K. 2003. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis 188:1054–1058. [PubMed]
52. Eriksen B. 1999. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180:1072–1079.
53. Shen J, Song N, Williams CJ, Brown CJ, Yan Z, Xu C, Forney LJ. 2016. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 6:24380. doi:10.1038/srep24380.
54. Mody L, Juthani-Mehta M. 2014. Urinary tract infections in older women: a clinical review. JAMA 311:844–854. [PubMed]
55. Stokholm J, Schjørring S, Eskildsen CE, Pedersen L, Bischoff AL, Følsgaard N, Carson CG, Chawes BL, Bønnelykke K, Mølgaard A, Jacobsson B, Krogfelt KA, Bisgaard H. 2014. Antibiotic use during pregnancy alters the commensal vaginal microbiota. Clin Microbiol Infect 20:629–635. [PubMed]
56. Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT. 2015. Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. J Infect Dis 212:793–802. [PubMed]
57. Macklaim JM, Clemente JC, Knight R, Gloor GB, Reid G. 2015. Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microb Ecol Health Dis 26:27799.
58. Smith HS, Hughes JP, Hooton TM, Roberts P, Scholes D, Stergachis A, Stapleton A, Stamm WE. 1997. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Clin Infect Dis 25:63–68. [PubMed]
59. Hooton TM, Roberts PL, Stapleton AE. 2012. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 307:583–589. [PubMed]
60. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120. [PubMed]
61. Eschenbach DA, Patton DL, Meier A, Thwin SS, Aura J, Stapleton A, Hooton TM. 2000. Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception 62:107–112. [PubMed]
62. Gupta K, Hillier SL, Hooton TM, Roberts PL, Stamm WE. 2000. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis 181:595–601. [PubMed]
63. Hooton TM, Hillier S, Johnson C, Roberts PL, Stamm WE. 1991. Escherichia coli bacteriuria and contraceptive method. JAMA 265:64–69. [PubMed]
64. Hooton TM, Scholes D, Roberts PL, Stapleton A, Stergachis A, Stamm WE. 1994. A prospective cohort study of the association between UTI and contraceptive method. Abstr Intersci Conf Antimicrob Agents Chemother 34:134.
65. Hooton TM, Fennell CL, Clark AM, Stamm WE. 1991. Nonoxynol-9: differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells. J Infect Dis 164:1216–1219. [PubMed]
66. Achilles SL, Hillier SL. 2013. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS 27(Suppl 1):S5–S15. [PubMed]
67. Stamm WE, McKevitt M, Roberts PL, White NJ. 1991. Natural history of recurrent urinary tract infections in women. Rev Infect Dis 13:77–84. [PubMed]
68. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. 2011. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52:1212–1217. [PubMed]
69. Schwenger EM, Tejani AM, Loewen PS. 2015. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 12:CD008772. [PubMed]
microbiolspec.UTI-0025-2016.citations
cm/4/6
content/journal/microbiolspec/10.1128/microbiolspec.UTI-0025-2016
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.UTI-0025-2016
2016-12-16
2017-12-16

Abstract:

The vagina is a key anatomical site in the pathogenesis of urinary tract infection (UTI) in women, serving as a potential reservoir for infecting bacteria and a site at which interventions may decrease the risk of UTI. The vaginal microbiota is a dynamic and often critical factor in this pathogenic interplay, because changes in the characteristics of the vaginal microbiota resulting in the loss of normally protective spp. increase the risk of UTI. These alterations may result from the influence of estrogen deficiency, antimicrobial therapy, contraceptives, or other causes. Interventions to reduce adverse effects on the vaginal microbiota and/or to restore protective lactobacilli may reduce the risks of UTI.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error